Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 4 (2007), Issue 10 (October)

1. The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity.
   Curr Opin Oncol, 19(6): 552-7. [Abstract] [Full-text]
2. Multiparameter noninvasive assessment of treatment susceptibility, drug target inhibition and tumor response guides cancer treatment.
   Int J Cancer, 121(11): 2492-500. [Abstract] [Full-text]
3. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
   Cancer Res, 67(19): 9018-23. [Abstract] [Full-text]
4. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.
   Clin Cancer Res, 13(19): 5883-8. [Abstract] [Full-text]
5. Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cut-off for amplification.
   Breast Cancer Res, 9(5): R64. [Abstract] [Full-text]
6. Thyroid cancer: are molecular studies making any difference?
   J Laryngol Otol, 121(10): 917-26. [Abstract] [Full-text]
7. Perspectives on the development of a therapeutic HER-2 cancer vaccine.
   Vaccine, 25: B17-23. [Abstract] [Full-text]
8. Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives.
   Crit Rev Oncol Hematol, 64(2): 115-28. [Abstract] [Full-text]
9. HER-2, TOP2A and Chromosome 17 Alterations in Breast Cancer.
   Pathol Oncol Res, 13(3): 180-5. [Abstract] [Full-text]
10. Targeting the function of the HER2 oncogene in human cancer therapeutics.
    Oncogene, 26(46): 6577-92. [Abstract] [Full-text]
11. The role of surgery in the management of older women with breast cancer.
    Eur J Cancer, 43(15): 2253-63. [Abstract] [Full-text]
12. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
    Cancer Cell, 12(4): 395-402. [Abstract] [Full-text]
13. PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?
    Cancer Cell, 12(4): 297-9. [Abstract] [Full-text]
14. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines.
    Mol Cancer Ther, 6(10): 2664-74. [Abstract] [Full-text]
15. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
    Cancer Res, 67(20): 9887-93. [Abstract] [Full-text]
16. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer.
    Clin Cancer Res, 13(20): 6080-6. [Abstract] [Full-text]
17. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
    J Control Release, 123(2): 164-71. [Abstract] [Full-text]
18. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy.
    Head Neck, 29(10): 907-12. [Abstract] [Full-text]
19. Analysis of surrogate markers for target-specific therapy in breast carcinomas using archival materials.
    Biomed Pharmacother, 61(9): 543-7. [Abstract] [Full-text]
20. Molecular systems biology in drug development.
    Clin Pharmacol Ther, 82(5): 586-90. [Abstract] [Full-text]
21. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
    Breast Cancer Res Treat. [Abstract] [Full-text]
22. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.
    Eur J Cancer, 43(16): 2423-2433. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.